<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04352114</url>
  </required_header>
  <id_info>
    <org_study_id>17517</org_study_id>
    <secondary_id>J2L-MC-EZBA</secondary_id>
    <nct_id>NCT04352114</nct_id>
  </id_info>
  <brief_title>A Study of LY3461767 in Healthy Participants</brief_title>
  <official_title>A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3461767 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study in healthy participants is to learn more about the safety of&#xD;
      LY3461767 and any side effects that might be associated with it. The study will also measure&#xD;
      how much LY3461767 gets into the bloodstream and how long it takes the body to get rid of it.&#xD;
      For each participant, the study will last about 11 weeks, including screening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2020</start_date>
  <completion_date type="Actual">January 13, 2021</completion_date>
  <primary_completion_date type="Actual">January 13, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3461767</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>PK: Cmax of LY3461767</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve (AUC) of LY3461767</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>PK: AUC of LY3461767</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3461767 - Subcutaneous (SC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3461767 administered SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - SC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3461767 - Intravenous (IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3461767 administered IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3461767 - SC</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>LY3461767 - Subcutaneous (SC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3461767 - IV</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>LY3461767 - Intravenous (IV)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - SC</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>Placebo - SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are healthy males, or females of non-child-bearing potential&#xD;
&#xD;
          -  Have a body mass index of 18 to 35 kilograms per square meter (kg/mÂ²)&#xD;
&#xD;
          -  Have clinical laboratory tests within normal ranges as judged by investigator&#xD;
&#xD;
          -  Have pulse rate and blood pressure within normal ranges as judged by investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have Troponin I results above the upper reference limit, and judged to be clinically&#xD;
             significant by the investigator, at screening&#xD;
&#xD;
          -  Have an abnormality in the 12-lead electrocardiogram (ECG) at screening&#xD;
&#xD;
          -  Have a significant history of or current cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal (GI), endocrine, hematological, or neurological disorders&#xD;
&#xD;
          -  Regularly use known drugs of abuse&#xD;
&#xD;
          -  Have donated blood of more than 450 milliliters (mL), or have participated in a&#xD;
             clinical study that required similar blood volume collected within the past 3 months&#xD;
&#xD;
          -  Have an average weekly alcohol intake that exceeds 7 units per week or are unwilling&#xD;
             to stop alcohol consumption as required during the study&#xD;
&#xD;
          -  Smoke more than 10 cigarettes per day&#xD;
&#xD;
          -  Are current or former smokers with 30-pack-year smoking history&#xD;
&#xD;
          -  Have a diagnosis or history of any malignancy&#xD;
&#xD;
          -  Have not had appropriate cancer screening, in accordance with country specific&#xD;
             guidance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lilly Nus Centre for Clin Pharmacology</name>
      <address>
        <city>Singapore</city>
        <zip>138623</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

